Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.
CDK4/6 inhibitor
Elderly
HER2
Metastatic breast cancer
SEER database
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
received:
25
03
2024
accepted:
13
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
aheadofprint
Résumé
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) in clinical trials and real-world studies. However, investigations of survival gains in broader HR+/HER2- mBC populations using epidemiological approaches are limited. This retrospective study used SEER registry data to assess breast cancer-specific survival (BCSS) in patients diagnosed with HR+/HER2- de novo mBC from 2010 to 2019. Kaplan-Meier and Cox proportional hazards models were used to compare BCSS in patients diagnosed before (2010‒2013 with follow-up to 2014) and after (2015‒2018 with follow-up to 2019) the 2015 guideline recommendations for CDK4/6i use. A comparison was made to patients with HR+/HER2-positive (HER2+) de novo mBC, for which no major guideline changes occurred during 2015-2018. Data from 11,467 women with HR+/HER2- mBC and 3260 women with HR+/HER2+ mBC were included. After baseline characteristic adjustment, patients with HR+/HER2- mBC diagnosed post-2015 (n = 6163), had an approximately 10% reduction in risk of BC-specific death compared with patients diagnosed pre-2015 (n = 5304; HR = 0.895, p < 0.0001). Conversely, no significant change was observed in HR+/HER2+ BCSS post-2015 (n = 1798) versus pre-2015 (n = 1462). Similar results were found in patients aged ≥ 65 years. Using one of the largest US population-based longitudinal cancer databases, significant improvements in BCSS were noted in patients with HR+/HER2- mBC post-2015 versus pre-2015, potentially due to the introduction of CDK4/6i post-2015. No significant improvement in BCSS was observed in patients with HR+/HER2+ mBC post-2015 versus pre-2015, likely due to the availability of HER2-directed therapies in both time periods.
Identifiants
pubmed: 39177933
doi: 10.1007/s10549-024-07469-6
pii: 10.1007/s10549-024-07469-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
SEER Explorer (2020) Surveillance Research Program, National Cancer Institute; 2023 Apr 19. Available from: https://seer.cancer.gov/statistics-network/explorer . Accessed Sep 2023
SEER (2020) Cancer stat facts: Female breast cancer subtypes. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html . Accessed Sep 2023
Howlader N, Cronin KA, Kurian AW, Andridge R (2018) Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev 27:619–626. https://doi.org/10.1158/1055-9965.EPI-17-0627
doi: 10.1158/1055-9965.EPI-17-0627
Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Dieras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Triki M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Perol D, Delaloge S (2021) Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open 6:100114. https://doi.org/10.1016/j.esmoop.2021.100114
doi: 10.1016/j.esmoop.2021.100114
pubmed: 33895695
pmcid: 8095121
Iwase T, Shrimanker TV, Rodriguez-Bautista R, Sahin O, James A, Wu J, Shen Y, Ueno NT (2021) Changes in overall survival over time for patients with de novo metastatic breast cancer. Cancers (Basel). https://doi.org/10.3390/cancers13112650
doi: 10.3390/cancers13112650
pubmed: 34638323
pmcid: 8464782
Sundquist M, Brudin L, Tejler G (2017) Improved survival in metastatic breast cancer 1985–2016. Breast 31:46–50. https://doi.org/10.1016/j.breast.2016.10.005
doi: 10.1016/j.breast.2016.10.005
pubmed: 27810699
US Food & Drug Administration (2015) Palbociclib (IBRANCE). https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance
US Food & Drug Administration (2017) Ribociclib (Kisqali). https://www.fda.gov/drugs/resources-information-approved-drugs/ribociclib-kisqali
US Food & Drug Administration (2018) FDA approves new treatment (Verzenio, abemaciclib) for certain advanced or metastatic breast cancers. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-advanced-or-metastatic-breast-cancers
Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21:4760–4766. https://doi.org/10.1158/1078-0432.ccr-15-1185
doi: 10.1158/1078-0432.ccr-15-1185
pubmed: 26324739
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439. https://doi.org/10.1016/S1470-2045(15)00613-0
doi: 10.1016/S1470-2045(15)00613-0
pubmed: 26947331
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925–1936. https://doi.org/10.1056/NEJMoa1607303
doi: 10.1056/NEJMoa1607303
pubmed: 27959613
Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM (2020) CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 21:250–260. https://doi.org/10.1016/s1470-2045(19)30804-6
doi: 10.1016/s1470-2045(19)30804-6
pubmed: 31859246
Gao JJ, Cheng J, Prowell TM, Bloomquist E, Tang S, Wedam SB, Royce M, Krol D, Osgood C, Ison G, Sridhara R, Pazdur R, Beaver JA, Amiri-Kordestani L (2021) Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncol 22:1573–1581. https://doi.org/10.1016/S1470-2045(21)00472-1
doi: 10.1016/S1470-2045(21)00472-1
pubmed: 34656225
Goetz MP (2023) MONARCH 3: final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy in patients with HR+, HER2− advanced breast cancer. Cancer Res Presentation at SABCS 2023. Abstract GS01-12.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638–3646. https://doi.org/10.1200/JCO.2017.75.6155
doi: 10.1200/JCO.2017.75.6155
pubmed: 28968163
Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML (2023) Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129:1051–1063. https://doi.org/10.1002/cncr.34675
doi: 10.1002/cncr.34675
pubmed: 36760031
Harbeck N, Bartlett M, Spurden D, Hooper B, Zhan L, Rosta E, Cameron C, Mitra D, Zhou A (2021) CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol 17:2107–2122. https://doi.org/10.2217/fon-2020-1264
doi: 10.2217/fon-2020-1264
pubmed: 33663223
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, Andre F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O’Shaughnessy J (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386:942–950. https://doi.org/10.1056/NEJMoa2114663
doi: 10.1056/NEJMoa2114663
pubmed: 35263519
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748. https://doi.org/10.1056/NEJMoa1609709
doi: 10.1056/NEJMoa1609709
pubmed: 27717303
Llombart-Cussac A, Sledge GW, Masakazu T, Neven P, Sohn JH, Inoue K, Pivot X, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Andre V, Bian Y, Shahir A, van Hal G (2023) PD13–11 Final overall survival analysis of Monarch 2: A phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Cancer Res 83:13–11. https://doi.org/10.1158/1538-7445.SABCS22-PD13-11
doi: 10.1158/1538-7445.SABCS22-PD13-11
Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A (2022) Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer 8:114. https://doi.org/10.1038/s41523-022-00479-x
doi: 10.1038/s41523-022-00479-x
pubmed: 36220852
pmcid: 9553912
Slamon D, Dieras V, Rugo HS, Harbeck N, Im SA, Gelmon K, Lipatov O, Walshe JM, Martin M, Mac Gregor MC, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS (2023) Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. https://doi.org/10.1200/JCO.23.00137
doi: 10.1200/JCO.23.00137
pubmed: 36921335
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortes J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623–1649. https://doi.org/10.1016/j.annonc.2020.09.010
doi: 10.1016/j.annonc.2020.09.010
pubmed: 32979513
McAndrew NP, Finn RS (2022) Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract 18:319–327. https://doi.org/10.1200/OP.21.00384
doi: 10.1200/OP.21.00384
pubmed: 34637323
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 34:3069–3103. https://doi.org/10.1200/JCO.2016.67.1487
doi: 10.1200/JCO.2016.67.1487
pubmed: 27217461
Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321:288–300. https://doi.org/10.1001/jama.2018.19323
doi: 10.1001/jama.2018.19323
pubmed: 30667505
Alvarez A, Bernal AM, Anampa J (2023) Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res Treat 198:75–88. https://doi.org/10.1007/s10549-022-06847-2
doi: 10.1007/s10549-022-06847-2
pubmed: 36562909
DCCPS. SRP (2020) National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/registries/terms.html .
Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598. https://doi.org/10.1093/jnci/djq366
doi: 10.1093/jnci/djq366
pubmed: 20937991
pmcid: 2957430
Chang JC, O’Regan R (2018) Use of novel combination therapies in the treatment of advanced HR+/HER2− breast cancer. J Natl Compr Canc Netw 16:S5–S17. https://doi.org/10.6004/jnccn.2018.0200
doi: 10.6004/jnccn.2018.0200
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465–2472. https://doi.org/10.1200/JCO.2018.78.9909
doi: 10.1200/JCO.2018.78.9909
pubmed: 29860922
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875–2884. https://doi.org/10.1200/JCO.2017.73.7585
doi: 10.1200/JCO.2017.73.7585
pubmed: 28580882
Llombart-Cussac A, Perez-Garcia JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Schmid P, Zamora P, Wheatley D, Martinez-de Deunas E, Amillano K, Anton A, Cottu P, Vinas G, Petit T, Tesarova P, Ceuva J, Colleoni M, Martinez del Prado MP, Andres R, Aguirre E, Diaz M, Vitorino S, Sampayo-Cordero M, Cortes J (2023) PARSIFAL-LONG: Extended follow-up of hormone receptorpositive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study. Cancer Res Presentation at SABCS 2023.
Cottu P, Ramsey SD, Sola-Morales O, Spears PA, Taylor L (2022) The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making. Breast 61:118–122. https://doi.org/10.1016/j.breast.2021.12.015
doi: 10.1016/j.breast.2021.12.015
pubmed: 34959093
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortes J, group Cs (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–530. https://doi.org/10.1016/S1470-2045(19)30863-0
doi: 10.1016/S1470-2045(19)30863-0
pubmed: 32171426
Ibragimova KIE, Geurts SME, Croes S, Erdkamp F, Heijns JB, Tol J, Vriens B, Aaldering KNA, Dercksen MW, Pepels M, Peters N, van de Winkel L, Tilli DJP, Vriens IJH, de Boer M, Tjan-Heijnen VCG (2021) Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Res Treat 188:571–581. https://doi.org/10.1007/s10549-021-06178-8
doi: 10.1007/s10549-021-06178-8
pubmed: 33743103
pmcid: 8260428
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72:524–541. https://doi.org/10.3322/caac.21754
doi: 10.3322/caac.21754
pubmed: 36190501
Singh H, Kanapuru B, Smith C, Fashoyin-Aje LA, Myers A, Kim G, Pazdur R (2017) FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US Food and Drug Administration. J Clin Oncol 35:10009. https://doi.org/10.1200/JCO.2017.35.15_suppl.10009
doi: 10.1200/JCO.2017.35.15_suppl.10009
Talarico L, Chen G, Pazdur R (2004) Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22:4626–4631. https://doi.org/10.1200/JCO.2004.02.175
doi: 10.1200/JCO.2004.02.175
pubmed: 15542812
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26:1547–1573. https://doi.org/10.1093/annonc/mdv249
doi: 10.1093/annonc/mdv249
pubmed: 26026162
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE (2014) American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32:1277–1280. https://doi.org/10.1200/JCO.2013.53.8009
doi: 10.1200/JCO.2013.53.8009
pubmed: 24638016
Jaber Chehayeb R, Hood A, Wang X, Miksad R, Schellhorn Mougalian S, Lustberg MB, Wang SY, Greenup RA, Pusztai L, Kunst N (2022) Treatment sequencing patterns and associated direct medical costs of metastatic breast cancer care in the United States, 2011 to 2021. JAMA Netw Open 5:e2244204. https://doi.org/10.1001/jamanetworkopen.2022.44204
doi: 10.1001/jamanetworkopen.2022.44204
pubmed: 36445704
pmcid: 9709649
Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T (2018) Current treatment patterns among postmenopausal women with HR+/HER2− metastatic breast cancer in US community oncology practices: an observational study. Adv Ther 35:482–493. https://doi.org/10.1007/s12325-018-0676-2
doi: 10.1007/s12325-018-0676-2
pubmed: 29582246
Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX (2019) Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Canc Netw 17:141–147. https://doi.org/10.6004/jnccn.2018.7094
doi: 10.6004/jnccn.2018.7094
pubmed: 30787127
pmcid: 6752198
Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K (2022) Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: a large institutional study. Int J Cancer 150:2025–2037. https://doi.org/10.1002/ijc.33959
doi: 10.1002/ijc.33959
pubmed: 35133007
pmcid: 9018572
Liu Y, Wu J, Ji Z, Chen L, Zou J, Zheng J, Lin W, Cai J, Chen Y, Zheng D, Chen Y, Li Z (2023) Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer 23:816. https://doi.org/10.1186/s12885-023-11322-2
doi: 10.1186/s12885-023-11322-2
pubmed: 37653504
pmcid: 10469949
SEER (2020) SEER registries: Number of persons by race and Hispanic ethnicity for SEER participants (2020 census data). Available from: https://seer.cancer.gov/registries/data.html . Accessed Feb 2024